Caenorhabditis elegans: A nematode infection model for pathogenic fungi

Methods in Molecular Biology

Volumn 845, Issue , 2012, Pages 447-454

  Muhammed, Maged ^a   Coleman, Jeffrey J ^a   Mylonakis, Eleftherios ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antifungal; Caenorhabditis elegans; Cryptococcus; Survival assay

Indexed keywords

ANTIFUNGAL AGENT;

ANIMAL; ARTICLE; CAENORHABDITIS ELEGANS; DISEASE MODEL; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PATHOGENICITY; SACCHAROMYCES CEREVISIAE;

ANIMALS; ANTIFUNGAL AGENTS; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; HOST-PATHOGEN INTERACTIONS; MICROBIAL SENSITIVITY TESTS; SACCHAROMYCES CEREVISIAE;

CAENORHABDITIS ELEGANS; FUNGI; HEXAPODA; NEMATODA;

EID: 84858136296     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-539-8_31     Document Type: Chapter

References (7)

1. Breger J, Fuchs BB, Aperis G, Moy TI, Ausubel FM, Mylonakis E (2007) Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog 3: e18.
2. Thakur JK, Arthanari H, Yang F, Pan SJ, Fan X, Breger J, Frueh DP, Gulshan K, Li DK, Mylonakis E, Struhl K, Moye-Rowley WS, Cormack BP, Wagner G, Näär AM (2008) A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 452: 604–609.
3. Mylonakis E, Ausubel FM, Perfect JR, Heitman J, Calderwood SB (2002) Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci USA 99: 15675–15680.
4. Johnson CH, Ayyadevara S, McEwen JE, Shmookler Reis RJ (2009) Histoplasma capsulatum and Caenorhabditis elegans: a simple nematode model for an innate immune response to fungal infection. Med Mycol 47: 808–813.
5. Tang RJ, Breger J, Idnurm A, Gerik KJ, Lodge JK, Heitman J, Calderwood SB, Mylonakis E (2005) Cryptococcus neoformans gene involved in mammalian pathogenesis identified by a Caenorhabditis elegans progeny-based approach. Infect Immun 73:8219–8225.
6. Tampakakis E, Okoli I, Mylonakis E (2008) A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nat Protocols 3: 1925–1931.
7. Okoli I, Coleman JJ, Tampakakis E, An WF, Holson E, Wagner E, Conery AL, Larkins FJ, Wu G, Stern A, Ausubel FM, Mylonakis E (2009) Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS ONE 4: e7025.